Metropolis Healthcare (METROPOLIS) Stock Overview
Provides pathology and related healthcare services in India and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 4/6 |
| Past Performance | 4/6 |
| Financial Health | 6/6 |
| Dividends | 3/6 |
METROPOLIS Community Fair Values
Create NarrativeSee what 9 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Metropolis Healthcare Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₹595.65 |
| 52 Week High | ₹609.05 |
| 52 Week Low | ₹412.25 |
| Beta | 0.21 |
| 1 Month Change | 5.19% |
| 3 Month Change | 12.24% |
| 1 Year Change | 12.13% |
| 3 Year Change | 63.75% |
| 5 Year Change | -25.53% |
| Change since IPO | 148.23% |
Recent News & Updates
Narrative Update • Sep 03
METROPOLIS: Inorganic Expansion And Higher Future P/E Will Shape Balanced Return Outlook
Analysts have lifted their price target fair value for Metropolis Healthcare from ₹508.64 to ₹540.80, citing updated assumptions around revenue growth, profit margins and a higher future P/E multiple that together reshape their view of the stock’s risk and return profile. What's in the News for Metropolis Healthcare Metropolis Healthcare appointed Deloitte Haskins & Sells Chartered Accountants LLP as statutory auditors at its 26th Annual General Meeting held on August 18, 2026.
Narrative Update • Aug 20
METROPOLIS: Acquisition-Led Expansion Will Drive Future Earnings Re-Rating
The analyst price target for Metropolis Healthcare has been revised to ₹655 from ₹609. Analysts cite updated fair value estimates, a small change in the discount rate, and refreshed assumptions around revenue growth, profit margins, and future P/E as key drivers of this shift.Analysis Article • Aug 07
Metropolis Healthcare Limited (NSE:METROPOLIS) Just Released Its First-Quarter Results And Analysts Are Updating Their Estimates
Last week, you might have seen that Metropolis Healthcare Limited ( NSE:METROPOLIS ) released its quarterly result to...
Narrative Update • Aug 06
METROPOLIS: Genomics Expansion And Acquisitions Will Drive Future Upside
Analysts have raised their price target for Metropolis Healthcare from ₹715 to ₹760, citing updated assumptions that include a slightly lower discount rate, a modestly higher revenue growth outlook, an improved profit margin profile and a somewhat lower future P/E multiple. What’s in the News for Metropolis Healthcare Board meeting scheduled on August 4, 2026 at 14:00 Indian Standard Time to consider and approve the unaudited standalone and consolidated financial results for the quarter ended June 30, 2026.Recent updates
Narrative Update • Sep 03
METROPOLIS: Inorganic Expansion And Higher Future P/E Will Shape Balanced Return Outlook
Analysts have lifted their price target fair value for Metropolis Healthcare from ₹508.64 to ₹540.80, citing updated assumptions around revenue growth, profit margins and a higher future P/E multiple that together reshape their view of the stock’s risk and return profile. What's in the News for Metropolis Healthcare Metropolis Healthcare appointed Deloitte Haskins & Sells Chartered Accountants LLP as statutory auditors at its 26th Annual General Meeting held on August 18, 2026.Narrative Update • Aug 20
METROPOLIS: Acquisition-Led Expansion Will Drive Future Earnings Re-Rating
The analyst price target for Metropolis Healthcare has been revised to ₹655 from ₹609. Analysts cite updated fair value estimates, a small change in the discount rate, and refreshed assumptions around revenue growth, profit margins, and future P/E as key drivers of this shift.Analysis Article • Aug 07
Metropolis Healthcare Limited (NSE:METROPOLIS) Just Released Its First-Quarter Results And Analysts Are Updating Their Estimates
Last week, you might have seen that Metropolis Healthcare Limited ( NSE:METROPOLIS ) released its quarterly result to...Narrative Update • Aug 06
METROPOLIS: Genomics Expansion And Acquisitions Will Drive Future Upside
Analysts have raised their price target for Metropolis Healthcare from ₹715 to ₹760, citing updated assumptions that include a slightly lower discount rate, a modestly higher revenue growth outlook, an improved profit margin profile and a somewhat lower future P/E multiple. What’s in the News for Metropolis Healthcare Board meeting scheduled on August 4, 2026 at 14:00 Indian Standard Time to consider and approve the unaudited standalone and consolidated financial results for the quarter ended June 30, 2026.Narrative Update • Jul 15
METROPOLIS: Aggressive Diagnostics Expansion And Acquisitions Will Likely Pressure Future Returns
The analyst price target for Metropolis Healthcare has been revised from ₹457.23 to ₹508.64 as analysts update their models for revenue growth, profit margins, and future P/E assumptions. What’s in the News for Metropolis Healthcare Metropolis Healthcare is focusing on genomics, next generation sequencing, specialty diagnostics and acquisitions as key areas for its next phase of growth, according to comments from executive chairperson Ameera Shah and managing director Surendran Chemmenkotil.Narrative Update • Jul 01
METROPOLIS: Future Expansion Will Rely On Acquisitions In Diagnostics
Metropolis Healthcare's analyst fair value estimate has been revised from approximately ₹2,144.53 to ₹608.60. Analysts point to slightly adjusted assumptions for revenue growth, profit margins, and future P/E as the key drivers of this change.Narrative Update • Jun 17
METROPOLIS: Genomics And Specialty Diagnostics Expansion Will Drive Future Upside
Analysts have kept their fair value estimate for Metropolis Healthcare steady at ₹715, citing only modest tweaks to revenue growth, profit margin and future P/E assumptions that do not materially change the overall valuation view. What’s in the News for Metropolis Healthcare Metropolis Healthcare is focusing on genomics, next-generation sequencing and specialty diagnostics as part of its next phase, according to comments from executive chairperson Ameera Shah and managing director Surendran Chemmenkotil, source: ET interview.Narrative Update • Jun 03
METROPOLIS: Genomics Expansion And Acquisitions Will Drive Future Upside
Analysts have revised their price target for Metropolis Healthcare to ₹715 from ₹678, reflecting updated assumptions for revenue growth, profit margins and a higher future P/E multiple. What's in the News Management is focusing on genomics, next-generation sequencing, specialty diagnostics and selected acquisitions as key areas for the next phase of business expansion, according to comments from executive chairperson Ameera Shah and managing director Surendran Chemmenkotil.Analysis Article • May 16
Metropolis Healthcare Limited (NSE:METROPOLIS) Released Earnings Last Week And Analysts Lifted Their Price Target To ₹606
Shareholders might have noticed that Metropolis Healthcare Limited ( NSE:METROPOLIS ) filed its annual result this time...Analysis Article • May 12
If EPS Growth Is Important To You, Metropolis Healthcare (NSE:METROPOLIS) Presents An Opportunity
The excitement of investing in a company that can reverse its fortunes is a big draw for some speculators, so even...Narrative Update • May 05
METROPOLIS: Planned Stock Split And Bonus Issue Will Support Further Upside
Analysts have lifted their price target on Metropolis Healthcare to ₹678.22, with slightly higher assumed revenue growth of 17.75% and a profit margin of 18.21%, partly offset by a marginally lower future P/E of 42.90x in their refreshed model. What's in the News Metropolis Healthcare has announced a planned stock split or significant stock dividend in a 4:1 ratio, scheduled for Mar 20, 2026 (Key Developments).Narrative Update • Apr 21
METROPOLIS: Planned Stock Split And Bonus Issue Will Support Further Upside
Analysts have nudged their price target on Metropolis Healthcare higher from ₹664.88 to ₹678.22, reflecting updated assumptions around slightly faster revenue growth and a modestly different profit and P/E profile. What's in the News Planned 4:1 stock split or significant stock dividend announced for Metropolis Healthcare Limited, scheduled for Mar 20, 2026 (company event filing).Narrative Update • Apr 06
METROPOLIS: Genomics Centre And Bonus Issue Will Support Further Upside
Analysts have revised their price target for Metropolis Healthcare from ₹2,600.00 to ₹664.88, reflecting updated assumptions around the discount rate, revenue growth, profit margin and future P/E. What's in the News Metropolis Healthcare has scheduled a board meeting for Feb 04, 2026 to consider and approve unaudited standalone and consolidated financial results for the quarter and nine months ended Dec 31, 2025, and to consider an issuance of bonus shares subject to shareholder approval (Key Developments).Narrative Update • Mar 23
METROPOLIS: Genomics Push And Bonus Share Plans Will Shape Steady Outlook
Analysts have revised their price target for Metropolis Healthcare from about ₹1,838 to roughly ₹457, reflecting updated assumptions around fair value, revenue growth, profit margins and future P/E expectations. What's in the News Board meeting on Feb 04, 2026 to consider and approve unaudited standalone and consolidated financial results for the quarter and nine months ended Dec 31, 2025, and to consider an issuance of bonus shares subject to shareholder approval (Key Developments).Narrative Update • Mar 09
METROPOLIS: Genomics Expansion And Potential Bonus Issue Will Shape Balanced Outlook
Analysts have trimmed their price target for Metropolis Healthcare slightly from ₹1,849.69 to ₹1,838.24, reflecting updated views on revenue growth, profit margins and future P/E assumptions while keeping the discount rate unchanged. What's in the News Board meeting scheduled for Feb 4, 2026 to review unaudited standalone and consolidated financial results for the quarter and nine months ended Dec 31, 2025, and to consider a bonus share issue subject to shareholder approval (company filing).Narrative Update • Feb 23
METROPOLIS: Genomics Push And Possible Bonus Issue Will Shape Balanced Outlook
Analysts have slightly increased their price target for Metropolis Healthcare to ₹1,849.69 from ₹1,846.32, citing updated assumptions that include marginally higher revenue growth, a modestly stronger profit margin and a lower future P/E multiple in their models. What's in the News Board meeting on Feb 04, 2026 to review unaudited standalone and consolidated financial results for the quarter and nine months ended Dec 31, 2025, and to consider a potential issuance of bonus shares, subject to shareholder approval (Key Developments).Narrative Update • Feb 08
METROPOLIS: Genomics Expansion And Bonus Share Plans Will Shape Balanced Outlook
Analysts have raised their fair value estimate for Metropolis Healthcare from ₹1,655 to about ₹1,846, citing updated assumptions around discount rates, revenue growth, profit margins and future P/E levels. What's in the News A board meeting is scheduled for February 4, 2026, to consider and approve unaudited standalone and consolidated financial results for the quarter and nine months ended December 31, 2025, and to consider issuance of bonus shares, subject to shareholder approval (Key Developments).Analysis Article • Jan 27
Earnings Tell The Story For Metropolis Healthcare Limited (NSE:METROPOLIS)
When close to half the companies in India have price-to-earnings ratios (or "P/E's") below 23x, you may consider...Narrative Update • Jan 25
METROPOLIS: Genomics Expansion And Upcoming Results Will Support Further Upside
Analysts have kept their price target for Metropolis Healthcare steady at ₹2,600. This reflects slightly higher revenue growth assumptions, a modestly softer profit margin outlook, and a small uptick in the future P/E multiple.Narrative Update • Jan 11
METROPOLIS: Upcoming Results And Potential Interim Dividend Will Support Upside
Analysts have maintained their price target on Metropolis Healthcare at ₹2,600, citing only modest tweaks in revenue growth, profit margin expectations, and forward P/E assumptions that keep their overall view broadly unchanged. What's in the News Board meeting scheduled on November 4, 2025, to consider and approve unaudited standalone and consolidated financial results for the quarter and half year ended September 30, 2025 (company filing).Analysis Article • Jan 06
There Are Reasons To Feel Uneasy About Metropolis Healthcare's (NSE:METROPOLIS) Returns On Capital
If we want to find a potential multi-bagger, often there are underlying trends that can provide clues. Firstly, we'll...Narrative Update • Dec 27
METROPOLIS: Upcoming Results And Interim Dividend Are Expected To Support Upside
Analysts have modestly revised their price target for Metropolis Healthcare upward to ₹2,600.00, citing slightly improved expectations for long term revenue growth and profit margins, despite largely unchanged valuation assumptions. What's in the News Board meeting scheduled for November 4, 2025, to review and approve unaudited standalone and consolidated financial results for the quarter and half year ended September 30, 2025 (company filing) Consideration of declaration of an interim dividend on equity shares for the financial year 2025-26 has been included on the November 4, 2025, board meeting agenda (company filing) Valuation Changes Fair Value: unchanged at ₹2,600.00 per share, indicating no revision to the core valuation anchor.Narrative Update • Dec 13
METROPOLIS: New Tech Subsidiary Will Support Stronger Profit Margins Ahead
Analysts have raised their fair value estimate for Metropolis Healthcare to ₹2,600 from ₹2,350, citing slightly stronger expectations for revenue growth, profit margins, and future valuation multiples. What's in the News Board meeting scheduled on November 4, 2025, to consider and approve unaudited standalone and consolidated financial results for the quarter and half year ended September 30, 2025, and to consider declaration of an interim dividend for FY 2025-26 (Key Developments) Incorporation of Metropolis Quality Solutions Private Limited as a wholly owned subsidiary in the healthcare technology space, effective September 15, 2025, to support technology led expansion (Key Developments) Initial capital subscription of 10,000 equity shares with a face value of INR 10 each in the newly incorporated subsidiary, funded via cash consideration (Key Developments) Valuation Changes Fair Value Estimate has risen modestly from ₹2,350 to ₹2,600, reflecting a more optimistic outlook on the company’s intrinsic value.Analysis Article • Nov 08
Earnings Miss: Metropolis Healthcare Limited Missed EPS By 6.4% And Analysts Are Revising Their Forecasts
Metropolis Healthcare Limited ( NSE:METROPOLIS ) came out with its quarterly results last week, and we wanted to see...Analysis Article • Nov 06
Metropolis Healthcare (NSE:METROPOLIS) Could Easily Take On More Debt
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' It's only natural to consider a company's...Narrative Update • Sep 06
Rural Market Expansion And Digitalization Will Transform Diagnostics
With both consensus revenue growth and net profit margin forecasts for Metropolis Healthcare remaining stable, analysts have left their fair value estimate unchanged at ₹2145. What's in the News Board meeting scheduled to consider and approve un-audited standalone and consolidated financial results for the quarter ended June 30, 2025, and to discuss other matters.Analysis Article • Jul 23
Metropolis Healthcare Limited's (NSE:METROPOLIS) Share Price Matching Investor Opinion
When close to half the companies in India have price-to-earnings ratios (or "P/E's") below 30x, you may consider...Analysis Article • May 16
Metropolis Healthcare Limited Just Missed Earnings - But Analysts Have Updated Their Models
Last week, you might have seen that Metropolis Healthcare Limited ( NSE:METROPOLIS ) released its full-year result to...Analysis Article • Apr 15
Metropolis Healthcare Limited's (NSE:METROPOLIS) P/E Is On The Mark
With a price-to-earnings (or "P/E") ratio of 53.9x Metropolis Healthcare Limited ( NSE:METROPOLIS ) may be sending very...
New Narrative • Feb 10
Expansion Into Specialty Diagnostics Will Strengthen Market Position
Strategic acquisitions and expansion in specialty diagnostics are expected to boost revenue, enhance test offerings, and improve net margins over time.Analysis Article • Nov 13
Metropolis Healthcare Limited (NSE:METROPOLIS) Just Reported Second-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?
Metropolis Healthcare Limited ( NSE:METROPOLIS ) came out with its quarterly results last week, and we wanted to see...Analysis Article • Aug 14
Metropolis Healthcare Limited (NSE:METROPOLIS) Just Reported And Analysts Have Been Lifting Their Price Targets
Metropolis Healthcare Limited ( NSE:METROPOLIS ) came out with its quarterly results last week, and we wanted to see...Analysis Article • May 24
Metropolis Healthcare Limited Just Missed EPS By 5.7%: Here's What Analysts Think Will Happen Next
It's been a good week for Metropolis Healthcare Limited ( NSE:METROPOLIS ) shareholders, because the company has just...Analysis Article • Mar 28
Why Investors Shouldn't Be Surprised By Metropolis Healthcare Limited's (NSE:METROPOLIS) P/E
Metropolis Healthcare Limited's ( NSE:METROPOLIS ) price-to-earnings (or "P/E") ratio of 71x might make it look like a...Analysis Article • Jan 13
Capital Allocation Trends At Metropolis Healthcare (NSE:METROPOLIS) Aren't Ideal
If you're not sure where to start when looking for the next multi-bagger, there are a few key trends you should keep an...Analysis Article • Dec 23
Metropolis Healthcare Limited's (NSE:METROPOLIS) Share Price Matching Investor Opinion
Metropolis Healthcare Limited's ( NSE:METROPOLIS ) price-to-earnings (or "P/E") ratio of 65.8x might make it look like...Analysis Article • Sep 08
Does Metropolis Healthcare (NSE:METROPOLIS) Have A Healthy Balance Sheet?
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...Analysis Article • Jun 20
Metropolis Healthcare (NSE:METROPOLIS) Could Be Struggling To Allocate Capital
What are the early trends we should look for to identify a stock that could multiply in value over the long term...Shareholder Returns
| METROPOLIS | IN Healthcare | IN Market | |
|---|---|---|---|
| 7D | 0.6% | 2.0% | -0.6% |
| 1Y | 12.1% | 4.8% | -0.1% |
Return vs Industry: METROPOLIS exceeded the Indian Healthcare industry which returned 4.8% over the past year.
Return vs Market: METROPOLIS exceeded the Indian Market which returned -0.1% over the past year.
Price Volatility
| METROPOLIS volatility | |
|---|---|
| METROPOLIS Average Weekly Movement | 4.3% |
| Healthcare Industry Average Movement | 5.1% |
| Market Average Movement | 5.7% |
| 10% most volatile stocks in IN Market | 8.9% |
| 10% least volatile stocks in IN Market | 3.4% |
Stable Share Price: METROPOLIS has not had significant price volatility in the past 3 months compared to the Indian market.
Volatility Over Time: METROPOLIS's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1980 | 4,484 | Surendran Chemmenkotil | www.metropolisindia.com |
Metropolis Healthcare Limited, together with its subsidiaries, provides pathology and related healthcare services in India and internationally. The company offers routine and specialised pathology tests; advanced diagnostics, including genetic, molecular, and cytogenetic testing; preventive healthcare packages and corporate wellness screening; clinical trial research, hospital lab management, and home collection services; radiology services, including X-ray, sonography and ECG; and next-generation sequencing services. It also provides diagnostic services for oncology, chronic and infectious diseases, gastroenterology, neurology, nephrology, and women and child health, as well as various health checkup and laboratory services.
Metropolis Healthcare Limited Fundamentals Summary
| METROPOLIS fundamental statistics | |
|---|---|
| Market cap | ₹124.83b |
| Earnings (TTM) | ₹2.02b |
| Revenue (TTM) | ₹17.10b |
61.3x
P/E Ratio7.2x
P/S RatioIs METROPOLIS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| METROPOLIS income statement (TTM) | |
|---|---|
| Revenue | ₹17.10b |
| Cost of Revenue | ₹3.81b |
| Gross Profit | ₹13.29b |
| Other Expenses | ₹11.28b |
| Earnings | ₹2.02b |
Last Reported Earnings
Jun 30, 2026
Next Earnings Date
n/a
| Earnings per share (EPS) | 9.72 |
| Gross Margin | 77.74% |
| Net Profit Margin | 11.79% |
| Debt/Equity Ratio | 15.2% |
How did METROPOLIS perform over the long term?
See historical performance and comparisonDividends
0.3%
Current Dividend Yield22%
Payout RatioCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/09/10 11:42 |
| End of Day Share Price | 2026/09/10 00:00 |
| Earnings | 2026/06/30 |
| Annual Earnings | 2026/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Metropolis Healthcare Limited is covered by 41 analysts. 19 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Hrishikesh Patole | 360 ONE Capital Market Private Limited |
| null null | 360 ONE Capital Market Private Limited |
| Rohit Bhat | 360 ONE Capital Market Private Limited |